Search Results
Search for other papers by A Bergougnoux in
Google Scholar
PubMed
INSERM Unité 1203 (DEFE), Université de Montpellier, Montpellier, France
Search for other papers by L Gaspari in
Google Scholar
PubMed
Search for other papers by M Soleirol in
Google Scholar
PubMed
Search for other papers by N Servant in
Google Scholar
PubMed
Search for other papers by S Soskin in
Google Scholar
PubMed
Search for other papers by S Rossignol in
Google Scholar
PubMed
Search for other papers by K Wagner-Mahler in
Google Scholar
PubMed
Search for other papers by J Bertherat in
Google Scholar
PubMed
Search for other papers by C Sultan in
Google Scholar
PubMed
Search for other papers by N Kalfa in
Google Scholar
PubMed
Département d'Endocrinologie et de Gynécologie Pédiatrique, Hôpital Arnaud de Villeneuve, Université de Montpellier, Montpellier, France
INSERM Unité 1203 (DEFE), Université de Montpellier, Montpellier, France
Search for other papers by F Paris in
Google Scholar
PubMed
. Women Men Testosterone (nmol/L) 0.5–2.0 7.6–27.0 DHT (nmol/L) 0.1–0.7 0.2–3.2 ∆4 (nmol/L) 1.7–10.0 1.5–6.4 DHEA-S (µmol/L) 1.3–11.1 2.8–15.3 FSH (IU/L) 3.5–12.5 1.5–12.4 LH (IU/L) 2
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
Search for other papers by Claire L Wood in
Google Scholar
PubMed
Search for other papers by Kieren G Hollingsworth in
Google Scholar
PubMed
Search for other papers by Edrina Bokaie in
Google Scholar
PubMed
Search for other papers by Eric Hughes in
Google Scholar
PubMed
John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
Search for other papers by Robert Muni-Lofra in
Google Scholar
PubMed
John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
Search for other papers by Anna Mayhew in
Google Scholar
PubMed
Search for other papers by Rod T Mitchell in
Google Scholar
PubMed
John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
Search for other papers by Michela Guglieri in
Google Scholar
PubMed
Search for other papers by Joseph McElvaney in
Google Scholar
PubMed
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
Search for other papers by Timothy D Cheetham in
Google Scholar
PubMed
John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
Search for other papers by Volker Straub in
Google Scholar
PubMed
Introduction Duchenne muscular dystrophy (DMD) is characterised by the absence of dystrophin protein and results in muscle cell fragility, inflammatory change, and the accumulation of fibrotic tissue and fat in skeletal muscles ( 1 ). Despite
Search for other papers by Rebeca Esquivel-Zuniga in
Google Scholar
PubMed
Search for other papers by Alan D Rogol in
Google Scholar
PubMed
testosterone levels in hypogonadal men ( 74 , 75 ) ( Fig. 1 ). Figure 1 The main mechanisms by which substance/drug abuse may decrease testosterone levels and sperm production are inhibition of GnRH production/secretion, increase in prolactin levels